<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00882440</url>
  </required_header>
  <id_info>
    <org_study_id>0954-011</org_study_id>
    <secondary_id>MK0954-011</secondary_id>
    <secondary_id>2009_574</secondary_id>
    <nct_id>NCT00882440</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Efficacy and Safety of Different Doses of Losartan Potassium (MK0954-011)</brief_title>
  <official_title>A Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Investigate the Antihypertensive Efficacy and Safety of Different Doses of DuP 753 (MK0954)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this study was to compare the antihypertensive efficacy of different doses of
      losartan compared to placebo and enalapril, in patients with supine diastolic blood pressure
      of 100-115 mmHg.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 1990</start_date>
  <completion_date type="Actual">January 1992</completion_date>
  <primary_completion_date type="Actual">August 1991</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8</measure>
    <time_frame>24 hours post dose at Baseline and Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Categories of Antihypertensive Response in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8</measure>
    <time_frame>24 hours post dose at Week 8</time_frame>
    <description>Patients in Category I (defined as &quot;excellent&quot; in protocol) if SuDBP was &lt;90 mmHg, Category II (defined as &quot;good&quot; in protocol) if SuDBP was ≥90 but decreased at least 10 mmHg, or Category III (defined as &quot;fair&quot; or &quot;inadequate&quot; in protocol) if SuDBP was ≥90 and decreased less than 10 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Peak Supine Diastolic Blood Pressure (SuDBP) at Week 8</measure>
    <time_frame>6 hours post dose at Baseline and 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">576</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losartan 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losartan 25 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losartan 50 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losartan 100 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losartan 150 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enalapril 20 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>losartan potassium</intervention_name>
    <description>losartan oral capsule (10, 25, 50, 100 or 150 mg) once daily for 8 weeks</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <other_name>MK0954</other_name>
    <other_name>Cozaar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule to losartan</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enalapril</intervention_name>
    <description>Enalapril 20 mg oral tablet taken once daily for 8 weeks</description>
    <arm_group_label>7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has been diagnosed with mild to moderate hypertension, with supine diastolic
             blood pressure of 100 to 115 mmHg

          -  Patient has no active medical problems other than essential hypertension that might
             affect blood pressure

          -  Patient has received no drug therapy that might affect blood pressure

        Exclusion Criteria:

          -  Prior exposure to losartan

          -  History of stroke

          -  History of myocardial infarction

          -  Atrial flutter or atrial fibrillation

          -  History of congestive Heart failure

          -  Known Sensitivity to ACE inhibitors

          -  Known positive test for HIV/AIDS or Hepatitis B

          -  Patient is being treated for acute ulcer disease

          -  History of chronic liver disease

          -  Actively treated diabetes mellitis

          -  Any known bleeding or platelet disorder

          -  Absence of one kidney

          -  Women of childbearing potential or who are breastfeeding

          -  Patient is abusing or has a history of alcoholism or drug addiction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <reference>
    <citation>Gradman AH, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely DB, Sweet CS. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension. 1995 Jun;25(6):1345-50.</citation>
    <PMID>7768585</PMID>
  </reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2009</study_first_submitted>
  <study_first_submitted_qc>April 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2009</study_first_posted>
  <results_first_submitted>April 17, 2009</results_first_submitted>
  <results_first_submitted_qc>April 17, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 10, 2009</results_first_posted>
  <last_update_submitted>August 17, 2015</last_update_submitted>
  <last_update_submitted_qc>August 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited at 28 sites in the United States. Primary Therapy Period: December, 1990-August, 1991</recruitment_details>
      <pre_assignment_details>Patients could be randomized after the 4-week placebo baseline period if their mean supine diastolic blood pressure (SuDBP) was 100-115 mmHg and ≤7 mmHg from the mean SuDBP after 2 weeks of placebo therapy, or after a 2-week placebo baseline period if 2 sets of SuDBP data were within 100-115 mmHg, ≥3 days apart and differed by ≤7 mmHg.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Losartan and Enalapril placebo orally once daily for 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Losartan 10 mg</title>
          <description>Losartan 10 mg orally once daily for 8 weeks</description>
        </group>
        <group group_id="P3">
          <title>Losartan 25 mg</title>
          <description>Losartan 25 mg orally once daily for 8 weeks</description>
        </group>
        <group group_id="P4">
          <title>Losartan 50 mg</title>
          <description>Losartan 50 mg orally once daily for 8 weeks</description>
        </group>
        <group group_id="P5">
          <title>Losartan 100 mg</title>
          <description>Losartan 100 mg orally once daily for 8 weeks</description>
        </group>
        <group group_id="P6">
          <title>Losartan 150 mg</title>
          <description>Losartan 150 mg orally once daily for 8 weeks</description>
        </group>
        <group group_id="P7">
          <title>Enalapril 20</title>
          <description>Enalapril 20 mg orally once daily for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="82"/>
                <participants group_id="P4" count="79"/>
                <participants group_id="P5" count="90"/>
                <participants group_id="P6" count="84"/>
                <participants group_id="P7" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="75"/>
                <participants group_id="P4" count="76"/>
                <participants group_id="P5" count="80"/>
                <participants group_id="P6" count="77"/>
                <participants group_id="P7" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Uncooperative</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Losartan and Enalapril placebo orally once daily for 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Losartan 10 mg</title>
          <description>Losartan 10 mg orally once daily for 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Losartan 25 mg</title>
          <description>Losartan 25 mg orally once daily for 8 weeks</description>
        </group>
        <group group_id="B4">
          <title>Losartan 50 mg</title>
          <description>Losartan 50 mg orally once daily for 8 weeks</description>
        </group>
        <group group_id="B5">
          <title>Losartan 100 mg</title>
          <description>Losartan 100 mg orally once daily for 8 weeks</description>
        </group>
        <group group_id="B6">
          <title>Losartan 150 mg</title>
          <description>Losartan 150 mg orally once daily for 8 weeks</description>
        </group>
        <group group_id="B7">
          <title>Enalapril 20</title>
          <description>Enalapril 20 mg orally once daily for 8 weeks</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="78"/>
            <count group_id="B2" value="80"/>
            <count group_id="B3" value="82"/>
            <count group_id="B4" value="79"/>
            <count group_id="B5" value="90"/>
            <count group_id="B6" value="84"/>
            <count group_id="B7" value="83"/>
            <count group_id="B8" value="576"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.3" spread="11.6"/>
                    <measurement group_id="B2" value="53.9" spread="12.3"/>
                    <measurement group_id="B3" value="52.8" spread="12.2"/>
                    <measurement group_id="B4" value="52.8" spread="10.3"/>
                    <measurement group_id="B5" value="54.0" spread="10.2"/>
                    <measurement group_id="B6" value="53.9" spread="10.8"/>
                    <measurement group_id="B7" value="51.9" spread="11.1"/>
                    <measurement group_id="B8" value="53.1" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="31"/>
                    <measurement group_id="B6" value="22"/>
                    <measurement group_id="B7" value="27"/>
                    <measurement group_id="B8" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="59"/>
                    <measurement group_id="B6" value="62"/>
                    <measurement group_id="B7" value="56"/>
                    <measurement group_id="B8" value="383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="66"/>
                    <measurement group_id="B6" value="64"/>
                    <measurement group_id="B7" value="64"/>
                    <measurement group_id="B8" value="438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SuDBP</title>
          <description>Supine Diastolic Blood Pressure (SuDBP)</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103.3" spread="3.8"/>
                    <measurement group_id="B2" value="104.3" spread="3.9"/>
                    <measurement group_id="B3" value="103.3" spread="3.7"/>
                    <measurement group_id="B4" value="104.0" spread="3.7"/>
                    <measurement group_id="B5" value="104.1" spread="4.2"/>
                    <measurement group_id="B6" value="103.4" spread="3.4"/>
                    <measurement group_id="B7" value="103.1" spread="3.7"/>
                    <measurement group_id="B8" value="103.7" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Categories of Antihypertensive Response in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8</title>
        <description>Patients in Category I (defined as &quot;excellent&quot; in protocol) if SuDBP was &lt;90 mmHg, Category II (defined as &quot;good&quot; in protocol) if SuDBP was ≥90 but decreased at least 10 mmHg, or Category III (defined as &quot;fair&quot; or &quot;inadequate&quot; in protocol) if SuDBP was ≥90 and decreased less than 10 mmHg.</description>
        <time_frame>24 hours post dose at Week 8</time_frame>
        <population>An &quot;all patients treated&quot; approach was employed that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Losartan and Enalapril placebo orally once daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Losartan 10 mg</title>
            <description>Losartan 10 mg orally once daily for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Losartan 25 mg</title>
            <description>Losartan 25 mg orally once daily for 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>Losartan 50 mg</title>
            <description>Losartan 50 mg orally once daily for 8 weeks</description>
          </group>
          <group group_id="O5">
            <title>Losartan 100 mg</title>
            <description>Losartan 100 mg orally once daily for 8 weeks</description>
          </group>
          <group group_id="O6">
            <title>Losartan 150 mg</title>
            <description>Losartan 150 mg orally once daily for 8 weeks</description>
          </group>
          <group group_id="O7">
            <title>Enalapril 20</title>
            <description>Enalapril 20 mg orally once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Categories of Antihypertensive Response in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8</title>
          <description>Patients in Category I (defined as &quot;excellent&quot; in protocol) if SuDBP was &lt;90 mmHg, Category II (defined as &quot;good&quot; in protocol) if SuDBP was ≥90 but decreased at least 10 mmHg, or Category III (defined as &quot;fair&quot; or &quot;inadequate&quot; in protocol) if SuDBP was ≥90 and decreased less than 10 mmHg.</description>
          <population>An &quot;all patients treated&quot; approach was employed that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="78"/>
                <count group_id="O5" value="89"/>
                <count group_id="O6" value="84"/>
                <count group_id="O7" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Category I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="29"/>
                    <measurement group_id="O6" value="28"/>
                    <measurement group_id="O7" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Category III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="39"/>
                    <measurement group_id="O5" value="41"/>
                    <measurement group_id="O6" value="44"/>
                    <measurement group_id="O7" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8</title>
        <time_frame>24 hours post dose at Baseline and Week 8</time_frame>
        <population>The primary analysis employed an &quot;all patients treated&quot; approach that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Losartan and Enalapril placebo orally once daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Losartan 10 mg</title>
            <description>Losartan 10 mg orally once daily for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Losartan 25 mg</title>
            <description>Losartan 25 mg orally once daily for 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>Losartan 50 mg</title>
            <description>Losartan 50 mg orally once daily for 8 weeks</description>
          </group>
          <group group_id="O5">
            <title>Losartan 100 mg</title>
            <description>Losartan 100 mg orally once daily for 8 weeks</description>
          </group>
          <group group_id="O6">
            <title>Losartan 150 mg</title>
            <description>Losartan 150 mg orally once daily for 8 weeks</description>
          </group>
          <group group_id="O7">
            <title>Enalapril 20</title>
            <description>Enalapril 20 mg orally once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8</title>
          <population>The primary analysis employed an &quot;all patients treated&quot; approach that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="78"/>
                <count group_id="O5" value="89"/>
                <count group_id="O6" value="84"/>
                <count group_id="O7" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="7.8"/>
                    <measurement group_id="O2" value="-7.9" spread="7.6"/>
                    <measurement group_id="O3" value="-6.8" spread="7.9"/>
                    <measurement group_id="O4" value="-10.1" spread="7.0"/>
                    <measurement group_id="O5" value="-9.9" spread="6.9"/>
                    <measurement group_id="O6" value="-9.7" spread="8.0"/>
                    <measurement group_id="O7" value="-11.2" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Peak Supine Diastolic Blood Pressure (SuDBP) at Week 8</title>
        <time_frame>6 hours post dose at Baseline and 8 weeks</time_frame>
        <population>An &quot;all patients treated&quot; approach was employed that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Losartan and Enalapril placebo orally once daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Losartan 10 mg</title>
            <description>Losartan 10 mg orally once daily for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Losartan 25 mg</title>
            <description>Losartan 25 mg orally once daily for 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>Losartan 50 mg</title>
            <description>Losartan 50 mg orally once daily for 8 weeks</description>
          </group>
          <group group_id="O5">
            <title>Losartan 100 mg</title>
            <description>Losartan 100 mg orally once daily for 8 weeks</description>
          </group>
          <group group_id="O6">
            <title>Losartan 150 mg</title>
            <description>Losartan 150 mg orally once daily for 8 weeks</description>
          </group>
          <group group_id="O7">
            <title>Enalapril 20</title>
            <description>Enalapril 20 mg orally once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Peak Supine Diastolic Blood Pressure (SuDBP) at Week 8</title>
          <population>An &quot;all patients treated&quot; approach was employed that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="87"/>
                <count group_id="O6" value="81"/>
                <count group_id="O7" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="8.7"/>
                    <measurement group_id="O2" value="-7.3" spread="9.4"/>
                    <measurement group_id="O3" value="-9.9" spread="8.5"/>
                    <measurement group_id="O4" value="-11.9" spread="9.2"/>
                    <measurement group_id="O5" value="-10.4" spread="8.9"/>
                    <measurement group_id="O6" value="-13.1" spread="9.0"/>
                    <measurement group_id="O7" value="-16.2" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Executive Vice President, Clinical and Quantitative Sciences</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

